SCHEMBL24205791

SCHEMBL24205791

CC(C)(C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SLC2A1 P11166 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ MAPK1 P28482 1/20 0.38
▸ LGALS8 O00214 3/20 0.36
▸ LGALS1 P09382 2/20 0.34
▸ LGALS3 P17931 2/20 0.34
▸ LGALS9 O00182 1/20 0.34
▸ PYGB P11216 1/20 0.34
▸ SLC28A3 Q9HAS3 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24205805 1.00 L3MBTL1 (0.44) L3MBTL1SLC2A1MAPTMAPK1LGALS8
SCHEMBL10820248 0.85 L3MBTL1 (0.40) L3MBTL1SLC2A1MAPTMAPK1
SCHEMBL27055122 0.83 L3MBTL1 (0.42) L3MBTL1SLC2A1MAPTMAPK1LGALS8
SCHEMBL22660060 0.82 L3MBTL1 (0.37) L3MBTL1SLC2A1MAPTMAPK1LGALS8
SCHEMBL19261576 0.80 L3MBTL1 (0.44) L3MBTL1SLC2A1MAPTMAPK1LGALS8
SCHEMBL19261577 0.80 L3MBTL1 (0.44) L3MBTL1SLC2A1MAPTMAPK1LGALS8
SCHEMBL19860207 0.79 L3MBTL1 (0.36) L3MBTL1SLC2A1MAPTMAPK1
SCHEMBL22511423 0.78 LGALS8 (0.46) L3MBTL1SLC2A1MAPK1LGALS8LGALS1
SCHEMBL22073978 0.78 LGALS8 (0.46) L3MBTL1SLC2A1MAPK1LGALS8LGALS1
SCHEMBL1696452 0.78 LGALS8 (0.46) L3MBTL1SLC2A1MAPK1LGALS8LGALS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017535-A1 INHIBITORS OF ALDOSE REDUCTASE BARCLAYS BANK PLC (GB) 2022-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017535-A1 INHIBITORS OF ALDOSE REDUCTASE PMM2, DPM1, BPGM L3MBTL1 628/4885SLC2A1 473/4885MAPT 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback